Prophylaxis of post-ERCP pancreatitis by the intravenous administration of the non-steroidal anti-inflammatory drug - Intravenous flurbiprofen axetil for prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis

Division of Gastroenterology and Hepatology, Department of Medicine,Nihon University School of Medicine, Tokyo, Japan0 sites400 target enrollmentFebruary 19, 2014

ConditionsPost-ERCP pancreatitis

Overview

Phase: 未知
Intervention: Not specified
Conditions: Post-ERCP pancreatitis
Sponsor: Division of Gastroenterology and Hepatology, Department of Medicine,Nihon University School of Medicine, Tokyo, Japan
Enrollment: 400
Status: Recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

February 19, 2014

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

Division of Gastroenterology and Hepatology, Department of Medicine,Nihon University School of Medicine, Tokyo, Japan

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

•The following patients were excluded: those with contraindications to flurbiprofen axetil, those who had taken any NSAID during the preceding week, those diagnosed with acute pancreatitis during the month before ERCP, those with an anticipated low risk of PEP (those with chronic calcific pancreatitis or a pancreatic head tumor or those undergoing routine biliary stent exchange), and those who did not agree to participate in the study.